

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 947 498 A1**

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:
06.10.1999 Bulletin 1999/40

(21) Application number: 97912527.5

(22) Date of filing: 20.11.1997

(51) Int. Cl.⁶: **C07C 205/32**, C07C 205/40,
C07C 201/12, C07F 7/18,
C07D 317/52, C07D 319/08,
C07C 215/60, C07C 217/10,
C07C 213/02, C07B 61/00,
B01J 31/22

(86) International application number:
PCT/JP97/04240

(87) International publication number:
WO 98/24753 (11.06.1998 Gazette 1998/23)

(84) Designated Contracting States:
CH DE FR GB LI

(30) Priority: 02.12.1996 JP 33642596

(71) Applicant: **CHISSO CORPORATION**
Osaka-shi Osaka 530-6591 (JP)

(72) Inventors:
• **SHIBASAKI, Masakatsu**
Mitaka-shi, Tokyo 181 (JP)


• **SASAI, Hiroaki**
Chiba-shi, Chiba 262 (JP)
• **URATA, Yasuo**
Yokohama-shi, Kanagawa 236 (JP)
• **FUJITA, Mamoru**
Yokohama-shi, Kanagawa 236 (JP)

(74) Representative: **HOFFMANN - EITLE**
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)

(54) **OPTICALLY ACTIVE NITRO ALCOHOL DERIVATIVES, OPTICALLY ACTIVE AMINO ALCOHOL DERIVATES, AND PROCESS FOR PREPARING THE SAME**


(57) Optically active 1-substituted phenyl-2-nitro alcohol derivatives having the formula (1)

(Formula 1)



and the process for producing thereof, and 1-substituted phenyl-2-amino alcohol derivatives having the formula (2)

(Formula 2)



and the process for producing thereof from the optically active 1-substituted phenyl-2-nitro alcohol derivatives. From these nitro alcohols, pharmaceuticals such as (R)-albutamin and (R)-salmeterol useful as a bronchodilator is obtained via optically active amino alcohols which are useful pharmaceutical intermediates.

EP 0 947 498 A1

Description

Technical Field

5 [0001] The present invention relates to optically active 1-substituted phenyl-2-nitro alcohol derivatives and the process for producing thereof, to optically active 1-substituted phenyl-2-amino alcohol derivatives and the process for producing thereof, and to the process for producing (R)-albutamin and (R)-salmeterol using these compounds.

[0002] The optically active nitro alcohols of the present invention are useful in the medical field, particularly as a synthetic intermediate of nitrogenous compounds useful for thrombotic diseases, for example, cerebral infarction, myocardial infarction, angina pectoris, and peripheral arterial occlusion; of optically active albuterol, optically active salmeterol, 10 (R)-albutamin, and optically active terbutaline hydrochloride which are useful as a bronchodilator; and of optically active bamethan sulfate useful as a vasodilator. And these compounds can be produced in high yields and industrially advantageously with the process for producing thereof of the present invention.

[0003] The optically active amino alcohols of the present invention can be obtained from the above optically active nitro alcohols, and they are also useful intermediates of pharmaceuticals such as a thrombolytic agent, a central nervous system agent, an antiadipogenous agent and an antiasthmatic agent.

Background Art

20 [0004] The optically active nitro alcohols of the present invention are novel substances obtained by the nitro-aldol reaction between nitromethane and benzaldehyde derivatives.

[0005] It is widely known that such a nitro-aldol reaction proceeds in the presence of a base. For example, in Japanese Patent Application Laid-Open No. 58-203950, there is disclosed the nitro-aldol reaction performed in the presence of triethylamine which gives a racemic modification of benznitro alcohol. And in Tetrahedron Letters (1975) p. 4057, 25 there is disclosed the reaction between 2-chlorobenzaldehyde and nitroethane under a catalyst of an optically active compound which gives an asymmetric nitro alcohol in which a substituent is a chloride.

[0006] Further, the present inventors has reported in Tetrahedron Letters (1993) Vol. 34, p. 2657 that the reaction between benzaldehyde and nitromethane under a catalyst of lanthanum-lithium-(R)-binaphthol complex at -50°C gives (S)-1-phenyl-2-nitro ethanol in a yield of 84% (40% e.e.), and when carried out under a catalyst of samarium-lithium-(R)-binaphthol complex at -40°C, the reaction gives the same compound in a yield of 90% (62% e.e.) ((R) or (S) in the name of each compound represents R or S isomer, respectively, showing the compound's configuration).

[0007] The yields and optical purities described above, however, are not satisfactory ones. In addition, an asymmetric nitro-aldol reaction of benzaldehyde compounds having a hydroxyl group or those having a hydroxyl group with a protecting group has not been found yet and the reaction products, optically active 1-substituted phenyl-2-nitro alcohol 35 derivatives, have not been known yet, either.

[0008] But at the same time, it is hoped now that pharmaceuticals produced from benznitro alcohol derivatives will be supplied in the form of a single optical isomer rather than in the form of a racemic modification. The reason is that, when only one type of structure is therapeutically effective, the other type of optically active substance is no better than impurities and likely to cause adverse effects. In order to meet such a demand, various types of asymmetric synthesis and 40 optical resolution of a racemic modification have been carried out as a method of obtaining pharmaceuticals of optically active substances.

[0009] However, as described above, the nitro-group containing compounds (intermediates) of the present invention have not been known yet, and the only example is (S)-1-phenyl-2-nitroethanol, which has no substituent, reported by the present inventors. Accordingly, the process for producing a group of pharmaceuticals which are to be produced from 45 optically active 1-substituted phenyl-2-nitro alcohol derivatives has not been known, either.

[0010] The optically active 1-substituted phenyl-2-amino alcohol derivatives of the present invention are a group of the compounds obtained from the novel optically active 1-substituted phenyl-2-nitro alcohol derivatives of the present invention.

[0011] On the other hand, as a method of producing optically active 1-substituted phenyl-2-amino alcohol derivatives, various types of asymmetric synthesis and optical resolution of a racemic modification have been carried out, and various processes for producing compounds similar to these ones have been also reported.

[0012] For example, as a method using optical resolution, in Japanese Patent Application Laid-Open No. 64-9979 (Japanese Patent Publication No. 4-48791), there is disclosed a method of producing (R) isomer of 2-amino-1-(3-chlorophenyl) ethanol from the racemic modification using N-(t-butoxycarbonyl)-D-alanine. And in Japanese Patent Application Laid-Open No. 2-85247, there is disclosed the method of subjecting the racemic modification of 2-amino-1-(4-chlorophenyl) ethanol to optical resolution using D-tartaric acid.

[0013] As a method using an asymmetric reduction reaction, for example, in Chemical and Pharmaceutical Bulletin (1995) vol. 43-5, p. 738, there is disclosed the process for producing (S)-1-phenyl-2-[N-(2-chloroethyl)] aminoethanol

hydrochloride from 2-[N-(2-chloroethyl)] aminophenone hydrochloride.

[0014] And as a method using microorganisms, for example, in Chemistry Express (1989) vol. 4-9, p.621, there is disclosed the process for producing optically active 2-amino-1-phenylethanol from 2-amino-1-phenylethanol and α -aminoacetophenone as raw materials by microorganisms of Staphyrococcus, Micrococcus, Rhodococcus, and Niseria.

[0015] Further, in Japanese Patent Application Laid-Open No. 8-98697, there is disclosed the process for producing optically active 2-amino-1-phenylethanol derivatives from 2-amino-1-phenylethanol derivatives using various microorganisms.

[0016] With the method using optical resolution, however, even if optical resolution is carried out perfectly, the maximum yield expected is only 50% per reaction, and moreover, it is difficult to collect the optically active substances desired in a good yield. Accordingly, in order to improve the yield of optically active substances, it becomes necessary to further racemize unnecessary chiral compounds and to carry out optical resolution of the obtained racemic modifications repeatedly. Thus, using optical resolution can not produce the optically active substances desired effectively and industrially, therefore it can not be a satisfactory method.

[0017] Further, with the method using a usual hydrogen-reduction reaction of which typical example is the above asymmetric reduction reaction, unless the hydrogen pressure is high, the reaction often does not proceed. Thus the method is not appropriate, and moreover, since it has to use a special catalyst, the treatment of the catalyst has been a problem.

[0018] For the reduction reaction of optically active nitro alcohols, U.S. Patent No. 5,099,067 reports that the reduction reaction of erythro/threo forms of β -nitro alcohol proceeds at room temperature by adding ammonium formate.

[0019] For example, in Japanese Patent Application Laid-Open No. 6-256270, the present inventors report that (S)-(-)-propranolol is obtained in a yield of 90% from (S)-3-(α -naphthoxy)nitropropane-2-ol in the presence of PtO_2 at 50°C under atmospheric pressure. Further, the present inventors report in Journal of the Organic Chemistry (1995) vol. 60, p. 7388 that 2-amino-1, 3-alkyldiol is obtained in a yield of 71% in the presence of Pd-C.

[0020] These reduction reactions, however, are limited to the cases where the reduction reaction occurs on racemic modifications, and where, when the reaction occurs on optically active substances, a phenyl group has no substituent or only chlor as a substituent. There is no prior art known which is related directly to the reduction reaction intended by the present invention during which a steric structure of phenyl group having a hydroxyl group is maintained.

[0021] A racemic modification of 1-phenyl-2-aminoethanol is a known compound, for example, in Japanese Patent Application Laid-Open No. 58-203950, there is disclosed the synthetic method in which 1-(3,4-dihydroxyphenyl)-2-nitroethanol is subjected to a catalytic hydrogen addition reaction using Raney nickel to proceed the reduction reaction quantitatively, so as to obtain a racemic modification of 1-(3,4-dihydroxyphenyl)-2-aminoethanol; however, the disclosure makes no concrete reference to the optically active substances of 1-substituted phenyl-2-aminoethanol.

[0022] Thus, optically active 1-substituted phenyl-2-nitroethanol derivatives have not existed to date, and the products obtained by the reduction of the nitro group thereof, optically active 1-substituted phenyl-2-aminoethanol derivatives, have not been produced.

[0023] On the other hand, 1-substituted phenyl-2-aminoethanol derivatives are widely known compounds as a useful pharmaceutical intermediate.

[0024] For example, European Patent No. 0,006,735 specification describes that the intended pharmaceuticals can be synthesized by reacting a racemic and optically active amino alcohol compound with a carbonyl compound or a halide; however, actually disclosed in its embodiments is only the process for producing racemic sarmeterol by reacting a racemic amino alcohol compound with a carbonyl compound or a halide.

[0025] In U.S. Patent No. 5,442,118 specification there is disclosed the process for producing (R)-albuterol and in European Patent Publication No. 0,422,889 specification there is disclosed the process for producing (R)-sarmeterol; however, their production process is long, and the intended compound is obtained from the optically active styrene oxane derivatives which have been obtained from acetophenone derivatives as a raw material. In these patents, there is no embodiment in which the optically active 1-substituted phenyl-2-nitroethanol derivatives of the present invention are used.

[0026] Thus, optically active 1-substituted phenyl-2-nitroethanol compounds have not existed to date, therefore, the process for producing optically active albutamin and optically active sarmeterol using optically active catechol amines obtained by the reduction of the nitro group thereof has not been known.


Disclosure of the Invention

[0027] The present invention has been made in light of the foregoing problems of the prior arts. Accordingly, it is an object of the present invention to provide optically active 1-substituted phenyl-2-nitro alcohol derivatives and optically active 1-substituted phenyl-2-amino alcohol derivatives obtained by reducing the optically active 1-substituted phenyl-2-nitro alcohol derivatives of the present invention both of which are useful as an intermediate of pharmaceuticals such as (R)-albutamin, (R)-sarmeterol, (R)-albuterol and (R)-terbutaline hydrochloride which are useful as a bronchodilator,

and bamethan sulfate which is useful as a vasohypotonic. Another object of the present invention is to provide a process for producing these compounds. And another object of the present invention is to provide (R)-albutamin and (R)-salmeterol produced using these compounds.

[0028] After concentrating their energy on the study to achieve the above objects, the present inventors came to know that, for the optically active nitro alcohol derivatives, a group of the intended compounds can be obtained using the group of rare earth metal complexes described by themselves in U.S. Patent No. 5,336,653 specification and Tetrahedron Letters (1993) vol. 34, p. 2657 etc. At the same time, the present inventors came to know that, for the optically active amino alcohol derivatives, a group of the intended compounds can be easily obtained by subjecting the optically active nitro alcohol derivatives obtained as above to catalytic hydrogen addition in an organic solvent. And the present inventors found that they can achieve the above objects with these knowledge and have finally completed the present invention.

[0029] Specifically, the optically active 1-substituted phenyl-2-nitro alcohol derivatives of the present invention are characterized by the following formula (1),




(Formula 1)

in which n and m represent the positive integers satisfying $0 < n + m \leq 5$; R_1 and R_2 represent a hydrogen atom or a hydroxyl-protective group, respectively, and when $n + m$ is 2 or more, R_1 and R_2 can either be independent of each other or form a ring among R_1 s, R_2 s, or R_1 s plus R_2 s; R_3 represents $-(CH_2)_l-$, in which l is 1, 2 or 3; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group.

[0030] Suitable examples of the optically active 1-(3, 4-dihydroxyphenyl)-2-nitro alcohols of the present invention are characterized by the following formula (1-1),

(Formula 1-1)




in which R_5 and R_6 represent a hydrogen atom or a hydroxyl-protective group, respectively, and they can either be independent of each other or form a ring; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group.

[0031] (R)-albutamin etc., useful as a pharmaceutical, can be produced from the compounds of the above group of which R_4 is a hydrogen atom and isomer type is R-type, by converting the nitro group into an amino group, reacting the amino group with a carbonyl compound or an alkyl halide compound, and then eliminating the hydroxyl-protective group.

[0032] Suitable examples of the optically active 1-(3-hydroxymethyl-4-hydroxyphenyl)-2-nitro alcohols of the present

invention are characterized by the following formula (1-2),

(Formula 1-2)




in which R_1 and R_2 represent a hydrogen atom or a hydroxyl-protective group, respectively, and they can either be independent of each other or form a ring; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group.

[0033] (R)-salmeterol, (R)-albuterol etc., useful as a pharmaceutical, can be produced from the compounds of the above group of which R_4 is a hydrogen atom and isomer type is R-type, by converting the nitro group into an amino group, reacting the amino group with a carbonyl compound or an alkyl halide compound, and then eliminating the hydroxyl-protective group.

[0034] Suitable examples of the optically active 1-(3,5-dihydroxyphenyl)-2-nitro alcohols of the present invention are characterized by the following formula (1-3),

(Formula 1-3)




in which R_1 and R_2 represent a hydrogen atom or a hydroxyl-protective group, respectively, and they can either be independent of each other or form a ring; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group.

[0035] Optically active terbutaline etc., useful as a bronchodilator, can be produced from the compounds of the above group of R_4 is a hydrogen atom, by converting the nitro group into an amino group, reacting the amino group with a carbonyl compound or an alkyl halide compound, and then eliminating the hydroxyl-protective group.

[0036] Suitable examples of the optically active 1-(4-hydroxyphenyl)-2-nitro alcohols of the present invention are characterized by the following formula (1-4),

(Formula 1-4)



in which R_1 represents a hydrogen atom or a hydroxyl-protective group, respectively, and it can either be independent of each other or form a ring; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group.

[0037] Optically active bamethan etc., useful as a vasohypotonic, can be produced from the compounds of the above group of which R_4 is a hydrogen atom, by converting the nitro group into an amino group, reacting the amino group of the amino alcohol with a carbonyl compound or an alkyl halide compound, and then eliminating the hydroxyl-protective group.

[0038] Other suitable examples of the optically active nitro alcohols of the present invention are as follows.

[0039] The optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivatives (optically active 1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol) of formula (1-1), in which R_4 is a hydrogen atom, and each of R_5 and R_6 is a t-butyldimethylsiloxy group.

[0040] Optically active albutamin etc. useful as a pharmaceutical can be produced from this compound by converting the nitro group into an amino group, reacting the optically active amino alcohol with a carbonyl compound (for example, 4-(4-methoxymethoxyphenyl)butanoic acid, etc.), and then eliminating the hydroxyl-protective group.

[0041] The optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivatives (optically active 1-(3,4-dimethoxyphenyl)-2-nitroethanol) of formula (1-1), in which R_4 is a hydrogen atom, and each of R_5 and R_6 is a methyl group.

[0042] Optically active albutamin etc. useful as a pharmaceutical can be produced from this compound by converting the nitro group into an amino group, reacting the amino alcohol with a carbonyl compound (for example, 4-(4-methoxymethoxyphenyl)butanoic acid, etc.), and then eliminating the hydroxyl-protective group.

[0043] The optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivatives (optically active 1-(3,4-dibenzyloxyphenyl)-2-nitroethanol) of formula (1-1), in which R_4 is a hydrogen atom, and each of R_5 and R_6 is a benzyl group.

[0044] Optically active albutamin etc. useful as a pharmaceutical can be produced from this compound by converting the nitro group into an amino group, reacting the optically active amino alcohol with a carbonyl compound (for example, 4-(4-methoxymethoxyphenyl)butanoic acid, etc.), and then eliminating the hydroxyl-protective group.

[0045] The optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivatives (optically active 1-(3,4-diacetoxyphenyl)-2-nitroethanol) of formula (1-1), in which R_4 is a hydrogen atom, and each of R_5 and R_6 is an acetyl group.

[0046] Optically active albutamin etc. useful as a pharmaceutical can be produced from this compound by converting the nitro group into an amino group, reacting the optically active amino alcohol with a carbonyl compound (for example, 4-(4-methoxymethoxyphenyl)butanoic acid, etc.), and then eliminating the hydroxyl-protective group.

[0047] The optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivatives (optically active α -nitromethyl-piperonyl alcohol) of formula (1-1), in which R_4 is a hydrogen atom, and R_5 and R_6 are cyclized with a methylene group.

[0048] Optically active albutamin etc. useful as a pharmaceutical can be produced from this compound by converting into an amino group, reacting the optically active amino alcohol with a carbonyl compound (for example, 4-(4-methoxymethoxyphenyl)butanoic acid, etc.), and then eliminating the hydroxyl-protective group.

[0049] The optically active 2,2-dimethyl- α -nitromethyl-1,3-benzodioxan-6-methanol of formula (1-2), in which R_4 is a hydrogen atom, and R_1 and R_2 are cyclized.

[0050] Optically active sarmeterol etc. useful as a pharmaceutical can be produced from this compound by converting into an amino group, reacting the amino group with a carbonyl compound, and then eliminating the hydroxyl-protective group.

[0051] The optically active 1-(3,5-dibenzyloxyphenyl)-2-nitroethanol of formula (1-3), in which R_4 is a hydrogen atom, and each of R_1 and R_2 is a benzyl group.


[0052] Optically active terbutaline etc. useful as a pharmaceutical can be produced from this compound by converting into an amino group, reacting the amino group with a carbonyl compound, and then eliminating the hydroxyl-protective group.

[0053] The optically active 1-(4-benzoyloxyphenyl)-2-nitroethanol of formula (1-4) set forth in claim 1, characterized

in that R_4 is a hydrogen atom and R_1 is a benzoyl group. Optically active bamethan etc. useful as a pharmaceutical can be produced from this compound by converting into an amino group, reacting the amino group with a carbonyl compound, and then eliminating the hydroxyl-protective group.

[0054] The process for stereoselectively producing optically active nitro alcohols of the present invention is characterized in that, when producing optically active 1-substituted phenyl-2-nitro alcohol derivatives, an aldehyde of the following formula (2),

(Formula 2)



in which R_5 and R_6 represent a hydrogen atom or a hydroxyl-protective group, respectively, and they can either be independent of each other or form a ring together; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group,

is reacted with a nitro alkane derivative of the following formula (3),




in which R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group,

in the presence of a rare earth metal complex having an optically active ligand.

[0055] Likewise, the process for stereoselectively producing optically active nitro alcohols of the present invention is characterized in that, when producing optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivatives, an aldehyde of the following formula (2-1),

(Formula 2-1)



in which R_5 and R_6 represent a hydrogen atom or a hydroxyl-protective group, respectively, and they can either be independent of each other or form a ring together; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group,

is reacted with a nitro alkane derivative of the following formula (3),




in which R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group,

in the presence of a rare earth metal complex having an optically active ligand.


[0056] Likewise, the process for stereoselectively producing optically active nitro alcohols of the present invention is characterized in that, when producing optically active 1-(3-hydroxymethyl-4-hydroxyphenyl)-2-nitro alcohol derivatives,

an aldehyde of the following formula (2-2),

(Formula 2-2)




in which R₁ and R₂ represent a hydrogen atom or a hydroxyl-protective group, respectively, and they can either be independent of each other or form a ring together; R₄ represents a hydrogen atom, an alkyl group, or a hydroxymethyl group, is reacted with a nitro alkane derivative of the following formula (3),




in which R₄ represents a hydrogen atom, an alkyl group, or a hydroxymethyl group, in the presence of a rare earth metal complex having an optically active ligand.

[0057] Likewise, the process for stereoselectively producing optically active nitro alcohols of the present invention is characterized in that, when producing optically active 1-(3,5-dihydroxyphenyl)-2-nitro alcohol derivatives, an aldehyde of the following formula (2-3),

(Formula 2-3)




in which R₁ and R₂ represent a hydrogen atom or a hydroxyl-protective group, respectively, and they can either be independent of each other or form a ring together; R₄ represents a hydrogen atom, an alkyl group, or a hydroxymethyl group, is reacted with a nitro alkane derivative of the following formula (3),



in which R₄ represents a hydrogen atom, an alkyl group, or a hydroxymethyl group, in the presence of a rare earth metal complex having an optically active ligand.

[0058] Likewise, the process for stereoselectively producing optically active nitro alcohols of the present invention is characterized in that, when producing optically active 1-(4-hydroxyphenyl)-2-nitro alcohol derivatives, an aldehyde of the following formula (2-4),

(Formula 2-4)



in which R₁ represents a hydrogen atom or a hydroxyl-protective group; R₄ represents a hydrogen atom, an alkyl group, or a hydroxymethyl group, is reacted with a nitro alkane derivative of the following formula (3),




in which R₄ represents a hydrogen atom, an alkyl group, or a hydroxymethyl group, in the presence of a rare earth metal complex having an optically active ligand.

[0059] Suitable examples of the process for stereoselectively producing optically active nitro alcohols of the present invention include the following embodiments.

[0060] The process for stereoselectively producing optically active nitro alcohol derivatives characterized in that, when producing an optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivative of the formula (1-1) in which R₄ is a hydrogen atom and each of R₅ and R₆ is a t-butyldimethylsiloxy group (optically active 1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol), an aldehyde of the following formula (4)


(Formula 4)



is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.

[0061] The process for stereoselectively producing optically active nitro alcohol derivatives characterized in that, when producing an optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivative of the formula (1-1) in which R₄ is a hydrogen atom and each of R₅ and R₆ is a methyl group (optically active 1-(3,4-dimethoxyphenyl)-2-nitroethanol), an aldehyde of the following formula (5)


(Formula 5)



is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.

[0062] The process for stereoselectively producing optically active nitro alcohol derivatives characterized in that, when producing an optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivative of the formula (1-1) in which R_4 is a hydrogen atom and each of R_5 and R_6 is a benzyl group (optically active 1-(3,4-dibenzyloxyphenyl)-2-nitroethanol), an aldehyde of the following formula (6)


(Formula 6)



is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.

[0063] The process for stereoselectively producing optically active nitro alcohol derivatives characterized in that, when producing an optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivative of the formula (1-1) in which R_4 is a hydrogen atom and each of R_5 and R_6 is an acetyl group (optically active 1-(3,4-diacetoxyphenyl)-2-nitroethanol), an aldehyde of the following formula (7)

(Formula 7)




is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.

[0064] The process for stereoselectively producing optically active nitro alcohol derivatives characterized in that, when

producing an optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivative of the formula (1-1) in which R_4 is a hydrogen atom and R_5 and R_6 are cyclized with a methylene group (optically active α -nitromethyl-piperonyl alcohol), an aldehyde of the following formula (8)


(Formula 8)



is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.

[0065] The process for stereoselectively producing optically active nitro alcohol derivatives characterized in that, when producing an optically active 2,2-dimethyl- α -nitromethyl-1,3-benzodioxane-6-methanol of the formula (1-2) in which R_4 is a hydrogen atom and R_1 and R_2 are cyclized, an aldehyde of the following formula (9)


(Formula 9)



is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.

[0066] The process for stereoselectively producing optically active nitro alcohol derivatives characterized in that, when producing an optically active 1-(3,5-dibenzoyloxyphenyl)-2-nitroethanol of the formula (1-3) in which R_4 is a hydrogen atom and each of R_1 and R_2 is a benzyl group, an aldehyde of the following formula (10)


(Formula 10)



is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.

[0067] The process for stereoselectively producing optically active nitro alcohol derivatives characterized in that, when producing optically active 1-(4-benzyloxyphenyl)-2-nitroethanol of the formula (1-4) as described in claim 1 in which R_4 is a hydrogen atom and R_1 is a benzoyl group, an aldehyde of the following formula (11)


(Formula 11)



is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.


[0068] In the process for stereoselectively producing optically active nitro alcohol derivatives as described above, the rare earth metal complexes as above are preferably prepared from an alkoxide of Y, La, Nd, Sm, Eu, Gd, Tb, Dy, Pr or Yb, or a trichloride of these rare earth metals; an optically active 1,1'-bi-2-naphthol derivative of the following formula (12)

(Formula 12)



or the following formula (13)

(Formula 13)




in which each of R_7 and R_8 independently represent a hydrogen atom, an alkyl group of $C_1 - C_4$, an ethynyl group, a trialkylsilylethynyl group, or a phenyl group, and R_7 can be at any position of 4, 5, 6 and 7, and R_8 at any position of 4', 5', 6' and 7';
and an alkaline metal compound of lithium, sodium, or potassium.

[0069] Further, in the process for stereoselectively producing optically active nitro alcohol derivatives as described above, it is more preferable that the rare earth metal complexes to be used are prepared in such a way that the composition ratio of the alkoxide or trichloride of the above rare earth metals, the optically active 1,1'-bi-2-naphthol compound, and the alkaline metal is within the range of 1:1-3:0-10.

[0070] The optically active 1-substituted phenyl-2-amino alcohol derivatives of the present invention are characterized by the following formula (14),


(Formula 14)



in which n and m represent the positive integers satisfying $0 < n + m \leq 5$; R_1 and R_2 represent a hydrogen atom or a hydroxyl-protective group, respectively, and when $n + m$ is 2 or more, R_1 and R_2 can either be independent of each other or form a ring among R_1 s, among R_2 s, and among R_1 (s) and R_2 (s); R_3 represents $-(CH_2)_1-$ in which 1 represents 0, 1, or 3; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group.

[0071] Suitable examples of the optically active 1-substituted phenyl-2-amino alcohol derivatives of the present invention are the optically active 1-(3,4-dihydroxyphenyl)-2-amino alcohol derivatives of the following formula (14-1)

(Formula 14-1)



in which R_5 and R_6 represent a hydrogen atom or a hydroxyl-protective group, respectively, and they can either be independent of each other or form a ring; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group.

[0072] And the process for producing the optically active amino alcohol derivatives of the present invention is characterized in that, when producing optically active 1-substituted phenyl-2-amino alcohol derivatives, the optically active 1-substituted phenyl-2-nitro alcohol derivatives described above are stereoselectively reduced.


[0073] Pharmaceuticals such as optically active albutamin and sarmeterol can be produced by reacting these optically active amino alcohol derivatives with a carbonyl compound or an alkyl halide so as to introduce an alkyl group etc. into the amino group, and then eliminating hydroxyl-protective group; therefore, the optically active nitro alcohol derivatives and optically active amino alcohols of the present invention are useful pharmaceutical intermediates.

[0074] Now the process for producing the optically active nitro alcohol derivatives of the present invention will be described below.

[0075] In general, nitro-aldol reaction between a benzaldehyde derivative and a nitro alkane proceeds in the presence of a basic catalyst. The asymmetric nitro-aldol reaction according to the present invention can be carried out by the reaction of a benzaldehyde derivative and a nitro alkane in the presence of a rare earth metal complex having an optically active ligand.


[0076] In this case, as a supplying source of an optically active ligand, preferable are optically active 1,1'-bi-2-naphthol derivatives of the following formula (12)

(Formula 12)



or the following formula (13)


(Formula 13)



in which R₇ and R₈ independently represent a hydrogen atom, an alkyl group of C₁ - C₄, an ethynyl group, a trialksilylethynyl group, or a phenyl group, and R₇ can be at any position of 4, 5, 6 and 7, and R₈ at any position of 4', 5', 6' and 7'.

[0077] The process for preparing a rare earth metal complex solution can be briefly illustrated by the following (reaction equation 1).

Reaction equation 1



#1 Stir overnight

#2 Rare earth metal complex solution

although the process is described in detail in the foregoing literature. This is exemplary of the process of this invention, and it is to be understood that the invention is not intended to be limited to the specific process.

[0078] The present invention uses only one type of isomer, R-type or S-type, of the above optically active binaphthols. For the optically active binaphthols, R_7 can be at any position of 3, 4, 5, 6 and 7, and R_8 at any position of 3', 4', 5', 6' and 7', and it is found at present that, in terms of yield and optical purity, good results are obtained particularly from the optically active binaphthol having substituents at 6 and 6' positions.

[0079] Examples of R_7 and R_8 include a hydrogen atom; an alkyl group of methyl, ethyl, propyl, isopropyl, n-butyl, s-butyl, or t-butyl; a phenyl group; an alkenyl group; a trialkylsilyl ethynyl group (in this case, alkyl includes methyl, ethyl, propyl, isopropyl, n-butyl, s-butyl, or t-butyl, two alkyls can be different from each other or can be the same); a cyano group; and a halogen; and any combination can be adopted.

[0080] Examples of the rare earth metals of the rare earth metal compounds include Y, La, Nd, Sm, Eu, Gd, Tb, Dy, Pr, and Yb, any of the metals can be used suitably.

[0081] Examples of the rare earth metal compounds include an alkoxide (including methoxide, ethoxide, propoxide, isopropoxide, n-butoxide, s-butoxide, and t-butoxide), a chloride (including both an anhydride and a hydride), and a nitrate, and any of them can be used preferably.

[0082] Examples of the alkaline metal compounds used for the preparation of rare earth metal complexes include alkylalkaline metals (for example, methyllithium and n-butyllithium), alkaline metal hydroxides (for example, lithium hydroxide, sodium hydroxide and potassium hydroxide).

[0083] Examples of solvents used in the preparation of a rare earth metal complex solution include THF; however, the present invention is not limited to the specific solvent, and any solvents can be used as long as they do not change the structure of the rare earth metal complexes. Examples other than THF include ether-based solvents (for example, die-

thyl ether and 1,4-dioxane), halogen-based solvents (for example, methylene chloride, chloroform, 1,1,1-trichloroethane and monochlorobenzene), hydrocarbon-based solvents (for example, benzene, toluene, n-hexane and n-heptane), and fatty acid esters (for example, ethyl acetate and methyl acetate), in addition, polar solvents such as dimethyl sulfoxide, N,N'-dimethylformamide, etc. can also be used. These solvents can be used in a single form or as a mixture of 2 or more types.

[0084] Examples of aldehydes used as a raw material for the process of the present invention include 2-hydroxybenzaldehyde, 3-hydroxybenzaldehyde, 4-hydroxybenzaldehyde, 2,3-dihydroxybenzaldehyde, 2,4-dihydroxybenzaldehyde, 2,5-dihydroxybenzaldehyde, 2,6-dihydroxybenzaldehyde, 3,4-dihydroxybenzaldehyde, 3,5-dihydroxybenzaldehyde, 2,3,4-trihydroxybenzaldehyde, 2,3,5-trihydroxybenzaldehyde, 2,3,6-trihydroxybenzaldehyde, 2,4,5-trihydroxybenzaldehyde, 2,4,6-trihydroxybenzaldehyde, 2-hydroxy-3-hydroxymethylbenzaldehyde, 2-hydroxy-4-hydroxymethylbenzaldehyde, 2-hydroxy-5-hydroxymethylbenzaldehyde, 2-hydroxy-6-hydroxymethylbenzaldehyde, 3-hydroxy-2-hydroxymethylbenzaldehyde, 3-hydroxy-4-hydroxymethylbenzaldehyde, 3-hydroxy-5-hydroxymethylbenzaldehyde, 3-hydroxy-6-hydroxymethylbenzaldehyde, 4-hydroxy-2-hydroxymethylbenzaldehyde, 4-hydroxy-3-hydroxymethylbenzaldehyde, 4-hydroxy-5-hydroxymethylbenzaldehyde, 4-hydroxy-6-hydroxymethylbenzaldehyde, and the compounds as above of which aromatic hydroxyl group is protected with a hydroxyl-protective group (for example, t-butyldimethylsilyl group).

[0085] Examples of hydroxyl-protective groups used in the present invention include a methyl group, a tetrahydropyranyl group, an allyl group, an isopropyl group, a t-butyl group, a benzyl group, an acetyl group, and a trimethylsilyl group which are described in Protective Groups in Organic Synthesis.

[0086] Now the process for producing the optically active amino alcohol derivatives of the present invention will be described.

[0087] The optically active 1-substituted phenyl-2-amino alcohol derivatives of the present invention are synthesized by dissolving the corresponding optically active 1-substituted phenyl-2-nitroethanol compounds in an organic solvent, dispersing a catalytic hydrogen addition catalyst, and subjecting the optically active 1-substituted phenyl-2-nitroethanol compounds to hydrogen addition under hydrogen pressure.

[0088] Examples of the organic solvents include alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, and esters such as methyl acetate, ethyl acetate, propyl acetate, butyl acetate, methyl butyrate, and ethyl butyrate; however, the present invention is not intended to be limited to the specific solvent, and these alcohols and esters can be used in a single form or as a mixture in desired proportions.

[0089] For the catalytic hydrogen addition catalysts, usual hydrogen addition catalysts are satisfactory, and the examples include Pt-C, Pd-C and PtO₂.

[0090] Although the present invention is not intended to be limited to the specific amount of catalyst, considering the reaction time, 0.01 wt% or more of catalyst is preferably added based on the substrate (nitro alcohol).

[0091] Further, although the present invention is not intended to be limited to the specific reaction temperature, considering the intramolecular dehydration of nitro alcohols and the racemization of the products, the temperature is preferably 50°C and below.

[0092] Further, although the present invention is not intended to be limited to the specific hydrogen pressure and preferably the pressure is in the range from 0.1 to 30 MPa, considering the production equipment, more preferably in the range from 0.1 to 1 MPa.

Best Mode for Carrying Out the Invention

[0093] The present invention is illustrated by the following embodiments and catalyst preparation examples, however, it is to be understood that the invention is not intended to be limited to the specific embodiments.

[0094] In each example, optical purity was determined by liquid chromatography (HPLC) (CHIRALPAK AD or CHIRALCEL OD by Daicel Chemical Industries, Ltd.). And ¹H-NMR was measured with JNM-EX-270 (270 MHz) by JEOL.

(Catalyst Preparation Example 1)

[Preparation of Rare Earth Metal Complex Solution A0]

[0095] 58.0 mg (0.103 mmol) of (S)-6,6'-bis(triethylsilyl)ethynyl)-1,1'-dihydroxy-2,2'-binaphthalene was dried in a vacuum at 50°C for 2 hours. (S)-6,6'-bis(trimethylsilyl)ethynyl)-1,1'-dihydroxy-2,2'-binaphthalene was dissolved in 880 µl of THF under an argon stream, and 172 µl of a solution of 11.3 mg (0.0344 mmol) of triisopropoxy samarium Sm(Oi-Pr)₃ in 0.2 mol/dm³ THF was added dropwise at 0°C. After stirring at room temperature for 30 minutes, 60 µl of a hexane solution of 1.72 mol/dm³ n-BuLi (0.103 mmol) was added dropwise at 0°C. Then, the solution was stirred at room temperature overnight and 35 µl of THF solution containing water (0.035 mmol) was added, so as to prepare 0.03 mol/dm³ THF solution of a complex catalyst (A0), as above.

(Catalyst Preparation Example 2)

[Preparation of Rare Earth Metal Complex Solution A1]

- 5 [0096] 54 μl of hexane solution of 1.72 mol/dm³ n-BuLi (0.103 mmol) was added dropwise to the rare earth metal complex solution A0, so as to prepare a rare earth metal complex solution A1.

(Catalyst Preparation Example 3)

- 10 [Preparation of Rare Earth Metal Complex Solution B0]

[0097] A rare earth metal complex solution B0 was prepared following the same procedure as in the preparation of the rare earth metal complex solution A0, except that lanthanum triisopropoxy La (Oi-Pr)₃ was used instead of samarium triisopropoxy Sm (Oi-Pr)₃.

15

(Catalyst Preparation Example 4)

[Preparation of Rare Earth Metal Complex Solution B1]

- 20 [0098] 54 μl of hexane solution of 1.72 mol/dm³ n-BuLi (0.093 mmol) was added dropwise to the rare earth metal complex solution B0, so as to prepare a rare earth metal complex solution B1.

(Catalyst Preparation Example 5)

- 25 [Preparation of Rare Earth Metal Complex Solution C0]

[0099] A rare earth metal complex solution C0 was prepared following the same procedure as in the preparation of the rare earth metal complex solution A0, except that dysprosium triisopropoxy Dy (Oi-Pr)₃ was used instead of Sm (Oi-Pr)₃.

30

(Catalyst Preparation Example 6)

[Preparation of Rare Earth Metal Complex Solution C1]

- 35 [0100] 54 μl of hexane solution of 1.72 mol/dm³ n-BuLi (0.093 mmol) was added dropwise to the rare earth metal complex solution C0, so as to prepare a rare earth metal complex solution C1.

(Catalyst Preparation Example 7)

- 40 [Preparation of Rare Earth Metal Complex Solution D0]

[0101] A rare earth metal complex solution D0 was prepared following the same procedure as in the preparation of the rare earth metal complex solution A0, except that gadolinium triisopropoxy Gd (Oi-Pr)₃ was used instead of Sm (Oi-Pr)₃.

45

(Catalyst Preparation Example 8)

[Preparation of Rare Earth Metal Complex Solution D1]

- 50 [0102] 54 μl of hexane solution of 1.72 mol/dm³ n-BuLi (0.093 mmol) was added dropwise to the rare earth metal complex solution D0, so as to prepare a rare earth metal complex solution D1.

(Catalyst Preparation Example 9)

- 55 [Preparation of Rare Earth Metal Complex Solution E0]

[0103] A rare earth metal complex solution E0 was prepared following the same procedure as in the preparation of the rare earth metal complex solution A0, except that praseodymium triisopropoxy Pr (Oi-Pr)₃ was used instead of Sm

(*Oi-Pr*)₃.

(Catalyst Preparation Example 10)

5 [Preparation of Rare Earth Metal Complex Solution E1]

[0104] 54 μ l of hexane solution of 1.72 mol/dm³ *n*-BuLi (0.093 mmol) was added dropwise to the rare earth metal complex solution E0, so as to prepare a rare earth metal complex solution E1.

10 (Catalyst Preparation Example 11)

[Preparation of Rare Earth Metal Complex Solution F1]

15 [0105] A metal complex solution was prepared following the same procedure as in the preparation of the rare earth metal complex solution A0, except that (R)-1,1'-dihydroxy-2,2'-binaphthalene was used instead of (S)-6,6'-bis(triethylsilylethynyl)-1,1'-dihydroxy-2, 2'-binaphthalene, after which 54 μ l of hexane solution of 1.72 mol/dm³ *n*-BuLi (0.093 mmol) was added dropwise, so as to prepare a rare earth metal complex solution F1.

(Example 1)

20

Synthesis of (R)-1-(3,4-di(*t*-butyldimethylsiloxy)phenyl)-2-nitroethanol

[0106] 100 mg (0.26 mmol) of 3,4-di(*t*-butyldimethylsiloxy)benzaldehyde was dissolved in 10 ml of THF under the atmosphere of argon at -40°C, and 0.30 ml of rare earth metal complex solution A1 was mixed into the solution. After stirring for 30 minutes, 79.3 mg (1.3 mmol) of nitromethane was added dropwise to the mixture. After 67-hour reaction time, 2 ml of 1 N aqueous solution of hydrochloric acid was added to stop the reaction. Then, after 50 ml of ethyl acetate was added, the mixture was subjected to oil-water separation twice with 20 ml of saturated salt solution and once with 20 ml of water, and the ethyl acetate layer was dehydrated with sodium sulfate anhydride and concentrated with an evaporator, followed by the purification of the concentrate by silica gel chromatography (*n*-hexane / acetone = 10 / 1), after which (R)-1-(3,4-di(*t*-butyldimethylsiloxy)phenyl)-2-nitroethanol with an optical purity of 92% e.e. was obtained in a yield of 93%.

35

¹H-NMR (CDCl₃) : δ 6.87 - 6.81 (m, 3H), 5.37 - 5.29 (m, 1H), 4.62 - 4.42 (m, 2H), 2.62 (br, 1H), 0.99 (s, 9H), 0.98 (s, 9H), 0.20 (s, 6H)

(Example 2)

Synthesis of (R)-1-(3,4-di(*t*-butyldimethylsiloxy)phenyl)-2-nitroethanol

40 [0107] 110 mg (0.29 mmol) of 3,4-di(*t*-butyldimethylsiloxy)benzaldehyde was dissolved in 10 ml of THF under the atmosphere of argon at -40°C, and 0.32 ml of rare earth metal complex solution A0 was mixed into the solution. After stirring for 30 minutes, 88.5 mg (1.45 mmol) of nitromethane was added dropwise to the mixture. After 67-hour reaction time, (R)-1-(3,4-di(*t*-butyldimethylsiloxy)phenyl)-2-nitroethanol with an optical purity of 92% e.e. was obtained in a yield of 74%.

45

(Example 3)

Synthesis of (R)-1-(3,4-dimethoxyphenyl)-2-nitroethanol

50 [0108] 100 mg (0.55 mmol) of 3,4-dimethoxybenzaldehyde was dissolved in 10 ml of THF under the atmosphere of argon at -40°C, and 0.60 ml of rare earth metal complex solution A1 was mixed into the solution. After stirring for 30 minutes, 168 mg (2.75 mmol) of nitromethane was added dropwise to the mixture. After 97-hour reaction time, (R)-1-(3,4-dimethoxyphenyl)-2-nitroethanol with an optical purity of 32% e.e. was obtained in a yield of 61%.

55

¹H-NMR (CDCl₃) : δ 6.94 - 6.85 (m, 3H), 5.47 - 5.38 (m, 1H), 4.66 - 4.46 (m, 2H), 3.90 (s, 3H), 3.89 (s, 3H), 2.73 (br, 1H)

(Example 4)

Synthesis of (R)-1-(3,4-dibenzyloxyphenyl)-2-nitroethanol

5 [0109] 100 mg (0.30 mmol) of 3,4-dibenzyloxybenzaldehyde was dissolved in 10 ml of THF under the atmosphere of argon at -40°C, and 0.33 ml of rare earth metal complex solution A1 was mixed into the solution. After stirring for 30 minutes, 91.6 mg (1.50 mmol) of nitromethane was added dropwise to the mixture. After 75-hour reaction time, (R)-1-(3,4-dibenzyloxyphenyl)-2-nitroethanol with an optical purity 59% e.e. was obtained in a yield of 90%.

10 ¹H-NMR (CDCl₃) : δ7.45 - 7.20 (m, 10H), 7.00 - 6.86 (m, 3H), 5.38 - 5.26 (m, 1H), 5.17 (s, 2H), 5.16 (s, 2H), 4.57 - 4.38 (m, 2H), 2.67 (br, 1H)

(Example 5)

15 Synthesis of (R)-1-(3,4-diacetoxyphenyl)-2-nitroethanol

[0110] 102 mg (0.43 mmol) of 3,4-diacetoxybenzaldehyde was dissolved in 10 ml of THF under the atmosphere of argon at -40°C, and 0.48 ml of rare earth metal complex solution A1 was mixed into the solution. After stirring for 30 minutes, 131 mg (2.15 mmol) of nitromethane was added dropwise to the mixture. After 68-hour reaction time, (R)-1-(3,4-diacetoxyphenyl)-2-nitroethanol with an optical purity of 59% e.e. was obtained in a yield of 87%.

20 ¹H-NMR (CDCl₃) : δ7.32 - 7.19 (m, 3H), 5.55 - 5.40 (m, 1H), 4.63 - 4.42 (m, 2H), 2.62 (br, 1H), 2.30 (s, 3H), 2.29 (s, 3H)

25 (Example 6)

Synthesis of (R)-1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol

[0111] 105 mg (0.28 mmol) of 3,4-di(t-butyldimethylsiloxy)benzaldehyde was dissolved in 10 ml of THF under the atmosphere of argon at -40°C, and 0.31 ml of rare earth metal complex solution D1 was mixed into the solution. After stirring for 30 minutes, 85.5 mg (1.40 mmol) of nitromethane was added dropwise to the mixture. After 61-hour reaction time, (R)-1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol with an optical purity of 87% e.e. was obtained in a yield of 86%.

35 (Example 7)

Synthesis of (R)-1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol

[0112] 100 mg (0.26 mmol) of 3,4-di(t-butyldimethylsiloxy)benzaldehyde was dissolved in 10 ml of THF under the atmosphere of argon at -40°C, and 0.31 ml of rare earth metal complex solution B1 was mixed into the solution. After stirring for 30 minutes, 79.3 mg (1.30 mmol) of nitromethane was added dropwise to the mixture. After 66-hour reaction time, (R)-1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol with an optical purity of 79% e.e. was obtained in a yield of 89%.

45 (Example 8)

Synthesis of (R)-1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol

[0113] 100 mg (0.26 mmol) of 3,4-di(t-butyldimethylsiloxy)benzaldehyde was dissolved in 10 ml of THF under the atmosphere of argon at -40°C, and 0.31 ml of rare earth metal complex solution E1 was mixed into the solution. After stirring for 30 minutes, 79.3 mg (1.30 mmol) of nitromethane was added dropwise to the mixture. After 66-hour reaction time, (R)-1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol with an optical purity of 84% e.e. was obtained in a yield of 86%.

55

(Example 9)

Synthesis of (R)-1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol

5 [0114] 102 mg (0.27 mmol) of 3,4-di(t-butyldimethylsiloxy)benzaldehyde was dissolved in 10 ml of THF under the atmosphere of argon at -40°C, and 0.30 ml of rare earth metal complex solution C1 was mixed into the solution. After stirring for 30 minutes, 82.4 mg (1.35 mmol) of nitromethane was added dropwise to the mixture. After 66-hour reaction time, (R)-1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol with an optical purity of 68% e.e. was obtained in a yield of 72%.

10

(Example 10)

Synthesis of (S)-1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol

15 [0115] The rare earth metal complex solution F1 (10 ml) and 0.80 g (13.0 mmol) of nitromethane were mixed and stirred together for 30 minutes under the atmosphere of nitrogen. A solution of 1.00 g (2.6 mmol) of 3,4-di(t-butyldimethylsiloxy)benzaldehyde dissolved in 20 ml of THF was added dropwise to the mixture. After 24-hour reaction time, (S)-1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol with an optical purity of 93% e.e. was obtained in a yield of 85%.

20

(Example 11)

Synthesis of (R)- α -nitromethyl-piperonyl alcohol

[0116] (R)- α -nitromethyl-piperonyl alcohol with an optical purity of 73% e.e. was obtained from piperonal using the
25 rare earth metal complex solution A1 under the atmosphere of argon at -40°C after 50-hour reaction time.

$^1\text{H-NMR}$ (CDCl_3) : δ 6.90 - 6.82 (m, 3H), 5.99 (s, 2H), 5.41 - 5.35 (m, 1H), 4.62 - 4.43 (m, 2H), 2.70 (br, 1H)

(Example 12)

30

Synthesis of optically active 1-(3,5-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol

[0117] 100 mg (0.26 mmol) of 3,5-di(t-butyldimethylsiloxy)benzaldehyde was dissolved in 10 ml of THF under the atmosphere of argon at -40°C, and 0.30 ml of rare earth metal complex solution A1 was mixed into the solution. After
35 stirring for 30 minutes, 159 mg (2.6 mmol) of nitromethane was added dropwise to the mixture. After 140-hour reaction time, optically active 1-(3,5-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol with an optical purity of 62% e.e. was obtained in a yield of 93%.

$^1\text{H-NMR}$ (CDCl_3) : δ 6.86 - 6.83 (m, 3H), 5.34 (m, 1H), 4.57 (dd, $J=13.3$, 9.4Hz, 1H), 4.46 (dd, $J=13.3$, 3.1Hz, 1H),
40 2.64 (d, $J=3.5$ Hz, 1H), 0.99 (s, 9H), 0.98 (s, 9H), 0.20 (s, 12H)

(Example 13)

Synthesis of optically active 1-(3,5-dibenzyloxyphenyl)-2-nitroethanol

45

[0118] 100mg (0.30mmol) of 3,5-dibenzyloxybenzaldehyde was dissolved in 10 ml of THF under the atmosphere of argon at -40°C, and 0.35 ml of rare earth metal complex solution A1 was mixed into the solution. After stirring for 30 minutes, 183 mg (3.0 mmol) of nitromethane was added dropwise to the mixture. After 71-hour reaction time, optically
50 active 1-(3,5-dibenzyloxyphenyl)-2-nitroethanol with an optical purity of 68% e.e. was obtained in a yield of 84%.

50

$^1\text{H-NMR}$ (CDCl_3) : δ 7.45 - 7.30 (m, 10H), 6.65 - 6.58 (m, 3H), 5.42 - 5.36 (m, 1H), 5.04 (s, 4H), 4.62 - 4.45 (m, 2H),
2.74 (d, 1H)

(Example 14)

55

Synthesis of optically active 1-(3,5-dibenzyloxyphenyl)-2-nitroethanol

[0119] 100 mg (0.3 mmol) of 3,5-dibenzyloxybenzaldehyde was dissolved in 10 ml of THF under the atmosphere of

argon at -40°C, and 0.32 ml of rare earth metal complex solution A1 was mixed into the solution. After stirring for 30 minutes, 183 mg (29.9 mmol) of nitromethane was added dropwise to the mixture. After 88-hour reaction time, optically active 1-(3,5-dibenzoyloxyphenyl)-2-nitroethanol with an optical purity of 88% e.e. was obtained in a yield of 100%.

¹H-NMR (CDCl₃) : δ7.45 - 7.30 (m, 10H), 6.65 - 6.58 (m, 3H), 5.42 - 5.36 (m, 1H), 5.04 (s, 4H), 4.62 - 4.45 (m, 2H), 2.74 (d, 1H)

(Example 15)

Synthesis of optically active 1-(3,5-diacetoxyphenyl)-2-nitroethanol

[0120] 102 mg (0.43 mmol) of 3,5-diacetoxybenzaldehyde was dissolved in 10 ml of THF under the atmosphere of argon at -40°C, and 0.45 ml of rare earth metal complex solution A1 was mixed into the solution. After stirring for 30 minutes, 262 mg (4.3 mmol) of nitromethane was added dropwise to the mixture. After 44-hour reaction time, optically active 1-(3,5-diacetoxyphenyl)-2-nitroethanol with an optical purity of 86% e.e. was obtained in a yield of 89%. ¹H-NMR (CDCl₃) : δ7.07 (d, 2H), 6.91 (t, 1H), 5.48 - 5.41 (m, 1H), 4.61 - 4.48 (m, 2H), 3.03 (d, 1H), 2.29 (s, 6H)

(Example 16)

Synthesis of optically active 1-(4-t-butyldimethylsiloxy-3-t-butyldimethylsilyloxymethylphenyl)-2-nitroethanol

[0121] The rare earth metal complex solution A1 (0.10 ml) and 66 mg (1.07 mmol) of nitromethane were stirred at -40°C for 30 minutes, then 0.39 ml of solution of 41 mg (0.11 mmol) of 4-t-butyldimethylsiloxy-3-t-butyldimethylsilyloxymethylbenzaldehyde in THF was added dropwise to the mixture. After 69-hour reaction time, optically active 1-(4-t-butyldimethylsiloxy-3-t-butyldimethylsilyloxymethylphenyl)-2-nitroethanol with an optical purity of 37% e.e. was obtained in a yield of 35%.

¹H-NMR (CDCl₃) : δ7.47 (d, j=2.0 Hz, 1H), 7.16 (dd, j=8.5, 2.0 Hz, 1H), 6.76 (d, j=8.5 Hz, 1H), 5.41 (ddd, j=9.5, 3.5, 3.0 Hz, 1H), 4.74 (s, 2H), 4.61 (dd, j=13.5, 9.0 Hz, 1H), 4.48 (dd, j=13.5, 3.0 Hz, 1H), 2.65 (d, j=3.5 Hz, 1H), 1.00 (s, 9H), 0.96 (s, 9H), 0.22 (s, 6H), 0.11 (s, 6H)

(Example 17)

Synthesis of optically active 2,2-dimethyl-1,3-benzodioxane-6-methanol

[0122] 100 mg (0.52 mmol) of 2,2-dimethyl-1,3-benzodioxane-6-acetaldehyde was dissolved in 1.9 ml of THF under the atmosphere of argon at -40°C, and the rare earth metal complex solution A1 was mixed into the solution. After stirring for 30 minutes, 318 mg (5.2 mmol) of nitromethane was added dropwise to the mixture. After 61-hour reaction time, optically active 2,2-dimethyl-1,3-benzodioxane-6-methanol with an optical purity of 87% e.e. was obtained in a yield of 86%.

(Example 18)

Synthesis of optically active 1-(4-t-butyldimethylsiloxy-3-t-butyldimethylsilyloxymethylphenyl)-2-nitroethanol

[0123] The rare earth metal complex solution B1 and 65 mg (1.07 mmol) of nitromethane were stirred at -40°C for 30 minutes, then 0.40 ml of solution of 42 g (0.11 mmol) of 4-t-butyldimethylsiloxy-3-t-butyldimethylsilyloxymethylbenzaldehyde in THF was added dropwise to the mixture. After 67-hour reaction time, optically active 1-(4-t-butyldimethylsiloxy-3-t-butyldimethylsilyloxymethylphenyl)-2-nitroethanol with an optical purity of 30% e.e. was obtained in a yield of 30%.

(Example 19)

Synthesis of optically active 1-(4-benzoyloxy-3-benzoyloxymethylphenyl)-2-nitroethanol

[0124] The rare earth metal complex solution A1 and 149 mg (2.44 mmol) of nitromethane were stirred at -40°C for 30 minutes, then 0.89 ml of solution of 88 mg (0.24 mmol) of 4-benzoyloxy-3-benzoyloxymethylbenzaldehyde in THF was added dropwise to the mixture. After 69-hour reaction time, optically active 1-(4-benzoyloxy-3-benzoyloxymethylphenyl)-2-nitroethanol with an optical purity of 30% e.e. was obtained in a yield of 30%.

phenyl)-2-nitroethanol with an optical purity of 64% e.e. was obtained in a yield of 86%.

(Example 20)

5 Synthesis of optically active 1-(4-benzoyloxyphenyl)-2-nitroethanol

[0125] Optically active 1-(4-benzoyloxyphenyl)-2-nitroethanol with an optical purity of 50% e.e. was obtained from 4-benzoyloxybenzaldehyde using the rare earth metal complex solution F1 under the atmosphere of nitrogen at -30°C after 24-hour reaction time.

10

(Example 21)

Synthesis of optically active 1-(4-benzoyloxyphenyl)-2-nitropropanol

15 [0126] (S,S)-1-(4-benzoyloxyphenyl)-2-nitropropanol (30% e.e.), the threo form / erythro form ratio is 1.8 / 1.0, was obtained from 4-benzoyloxybenzaldehyde and nitroethane using the rare earth metal complex solution F1 under the atmosphere of nitrogen at -30°C after 24-hour reaction time.

(Example 22)

20

Synthesis of (R)-(-)-1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-aminoethanol

[0127] 100 mg of optically active 1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol obtained in example 1 was dissolved in 10 ml of methanol, and 10 mg of 10% Pd/C was added to the solution, after which the mixture was reacted at 25 20°C under the hydrogen pressure of 0.1 MPa for 20 hours, so as to obtain 89.3 mg of the intended compound (in a yield of 96%, with an optical purity of 94% e.e.).

IR (neat) cm^{-1} : 3859, 2928

1H-NMR (CDCl_3): δ 6.85 - 6.76 (m, 3H), 4.54 (dd, $j=8.0, 4.0$ Hz, 1H), 2.97 (dd, $j=12.0, 4.0$ Hz, 1H), 2.81 (dd, $j=12.0, 8.0$ Hz, 1H), 0.98 (s, 18H), 0.19 (s, 12H)

13C-NMR (CDCl_3 , 97.9MHz): 146.7, 146.3, 135.5, 120.8, 118.8, 73.7, 49.1, 25.9, 18.4, -4.1

$[\alpha]_D^{25} = -21.9$ (c1.15, CHCl_3)

(Example 23)

35

Synthesis of (S)-1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-aminoethanol

[0128] 98 mg of (S)-1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol obtained in example 10 was dissolved in 10 ml of methanol, and 10 mg of 10% Pd/C was added to the solution, after which the mixture was reacted at 20°C under the hydrogen pressure of 0.3 MPa for 5 hours, so as to obtain 85 mg of the intended compound.

40

$[\alpha]_D^{25} = +21.5$ (c1.10, CHCl_3)

(Example 24)

45

Synthesis of optically active 1-(3,5-dibenzoyloxyphenyl)-2-aminoethanol

[0129] The intended compound with an optical purity of 12% e.e. was obtained in a yield of 12% from the optically active 1-(3,5-dibenzoyloxyphenyl)-2-nitroethanol obtained in example 14 using 10% Pd/C.

50

$[\alpha]_D^{25} = -2.3$ (c0.32, EtOH)

(Example 25)

55 Synthesis of optically active 1-(4-t-butyldimethylsiloxy-3-t-butyldimethylsilyloxymethylphenyl)-2-aminoethanol

[0130] The intended compound was obtained from the optically active 1-(4-t-butyldimethylsiloxy-3-t-butyldimethylsilyloxymethylphenyl)-2-nitroethanol obtained in example 18 using 10% Pd/C.

$$[\alpha]^{25}_D = -2.9 \text{ (c0.35, EtOH)}$$

(Example 26)

5 Synthesis of optically active α -aminomethyl-2,2-dimethyl-1,3-benzodioxane-6-methanol

[0131] The intended compound was obtained from the optically active 2,2-dimethyl- α -nitromethyl-1,3-benzodioxane-6-methanol obtained in example 17 using 10% Pd/C.

$$10 \quad [\alpha]^{25}_D = -2.2 \text{ (c0.25, EtOH)}$$

(Example 27)

Synthesis of (R)-albutamin

15 [0132] 89.3 mg of (-)-1-(3,4-di(t-butylidimethylsiloxy)phenyl)-2-aminoethanol, 50.0 mg of 4-(4-methoxymethoxyphenyl)butanoic acid, diethylphosphorylcyanoide, and triethylamine were dissolved in N, N-dimethylformamide at 0°C, reacted at room temperature, so as to obtain 108.6 mg (in a yield of 82%) of amide compound. The amide compound obtained was reduced with lithium aluminium halide in an ether solvent at reflux temperature, so as to quantitatively
20 obtain amine. And 55.6 mg of (R)-albutamin which is the intended compound was obtained by deprotecting the hydroxyl-protective group of the amine in a methanol - THF solvent at room temperature using hydrochloric acid.

$$[\alpha]^{25}_D = -17 \text{ (c1.15, EtOH)}$$

25 (Example 28)

Synthesis of (R)-sarmeterol

30 [0133] Amine was obtained from the optically active 2,2-dimethyl- α -aminomethyl-1, 3-benzodioxane-6-methanol synthesized in example 26 and 6-(1-phenyl-butoxy) hexaaldehyde through subjecting them to reduction and amination, then the hydroxyl-protective group of the amine compound was deprotected using hydrochloric acid, so as to obtain the intended compound, (R)-sarmeterol. The angle of rotation was measured using the compound's salt of hydroxy naphthoic acid.

$$35 \quad [\alpha]^{25}_D = -3.1 \text{ (c0.30, MeOH)}$$

Industrial Availability

40 [0134] As described above, according to the present invention, optically active 1-substituted phenyl-2-nitro alcohol derivatives and optically active 1-substituted phenyl-2-amino alcohol derivatives, which are useful as pharmaceutical intermediates, and, in addition, the process for producing these compounds can be provided using a specific group of rare earth metal complexes.

[0135] Specifically, according to the present invention, optically active 1-substituted phenyl-2-nitro alcohol derivatives which are used as a material for pharmaceuticals, such as (R)-albutamin, have been synthesized, and the process for
45 producing thereof has been established.

[0136] At the same time, the process for producing optically active 1-substituted phenyl-2-amino alcohol derivatives which are to become useful intermediates of pharmaceuticals from optically active 1-substituted phenyl-2-nitro alcohol derivatives has been established, and the process for producing pharmaceuticals, (R)-albutamin and (R)-sarmeterol, from optically active 1-substituted phenyl-2-amino ethanol derivatives has been established.


50

Claims

1. Optically active 1-substituted phenyl-2-nitro alcohol derivatives characterized by the following formula (1)

55


(Formula 1)



in which n and m represent the positive integers satisfying $0 < n + m \leq 5$; R_1 and R_2 represent a hydrogen atom or a hydroxyl-protective group, respectively, and when $n + m$ is 2 or more, R_1 and R_2 are independent of each other or form a ring among R_1 s, among R_2 s, and among R_1 (s) and R_2 (s); R_3 represents $-(CH_2)_l-$ in which l is 0, 1, 2 or 3; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group; and $*$ represents an optically active site, and when R_4 is a hydrogen atom, optical activity at the site to which R_4 is added is lost and $*$ is omitted.

2. Optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivatives characterized by the following formula (1-1)


(Formula 1-1)



in which R_5 and R_6 represent a hydrogen atom or a hydroxyl-protective group, respectively, and they are independent of each other or form a ring; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group; and $*$ represents an optically active site, and when R_4 is a hydrogen atom, optical activity at the site to which R_4 is added is lost and $*$ is omitted.

3. Optically active 1-(3-hydroxymethyl-4-hydroxyphenyl)-2-nitro alcohol derivatives characterized by the following formula (1-2)

(Formula 1-2)




in which R_1 and R_2 represent a hydrogen atom or a hydroxyl-protective group, respectively, and they are independent

ent of each other or form a ring; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group; and * represents an optically active site, and when R_4 is a hydrogen atom, optical activity at the site to which R_4 is added is lost and * is omitted.

4. Optically active 1-(3,5-dihydroxyphenyl)-2-nitro alcohol derivatives characterized by the following formula (1-3)


(Formula 1-3)



in which R_1 and R_2 represent a hydrogen atom or a hydroxyl-protective group, respectively, and they are independent of each other or form a ring; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group; and * represents an optically active site, and when R_4 is a hydrogen atom, optical activity at the site to which R_4 is added is lost and * is omitted.

5. Optically active 1-(4-hydroxyphenyl)-2-nitro alcohol derivatives characterized by the following formula (1-4)

(Formula 1-4)




in which R_1 represents a hydrogen atom or a hydroxyl-protective group; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group; and * represents an optically active site, and when R_4 is a hydrogen atom, optical activity at the site to which R_4 is added is lost and * is omitted.

6. The optically active 1-(3,4-di(t-butyldimethylsiloxy)phenyl)-2-nitroethanol according to claim 2, characterized in that R_4 represents a hydrogen atom, and both R_5 and R_6 represent a t-butyldimethylsiloxy group.
7. The optically active 1-(3,4-dimethoxyphenyl)-2-nitroethanol according to claim 2, characterized in that R_4 represents a hydrogen atom, and both R_5 and R_6 represent a methyl group.
8. The optically active 1-(3,4-dibenzyloxyphenyl)-2-nitroethanol according to claim 2, characterized in that R_4 represents a hydrogen atom, and both R_5 and R_6 represent a benzyl group.
9. The optically active 1-(3,4-diacetoxyphenyl)-2-nitroethanol according to claim 2, characterized in that R_4 represents a hydrogen atom, and both R_5 and R_6 represent an acetyl group.

10. The optically active α -nitromethyl-piperonyl alcohol according to claim 2, characterized in that R_4 represents a hydrogen atom, and R_5 and R_6 are cyclized with a methylene group.
11. The optically active 2,2-dimethyl- α -nitromethyl-1,3-benzodioxane-6-methanol according to claim 3, characterized in that R_4 represents a hydrogen atom, and R_1 and R_2 are cyclized.
12. The optically active 1-(3,5-dibenzyloxyphenyl)-2-nitroethanol according to claim 4, characterized in that R_4 represents a hydrogen atom, and both R_1 and R_2 represent a benzyl group.
13. Optically active 1-(4-benzyloxyphenyl)-2-nitroethanol according to claim 5, characterized in that R_4 represents a hydrogen atom and R_1 represents a benzyl group.
14. A process for stereoselectively producing optically active nitro alcohol derivatives, characterized in that an aldehyde of the following formula (2)

(Formula 2)




in which n and m represent the positive integers satisfying $0 < n + m \leq 5$; R_1 and R_2 represent a hydrogen atom or a hydroxyl-protective group, respectively, and when $n + m$ is 2 or more, R_1 and R_2 are independent of each other or form a ring among R_1 s, among R_2 s, and among R_1 (s) and R_2 (s); R_3 represents $-(CH_2)_l-$ in which l is 0, 1, 2 or 3; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group; is reacted with a nitro alkane derivative of the following formula (3)



in which R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group, in the presence of a rare earth metal complex having an optically active ligand.

15. A process for stereoselectively producing optically active nitro alcohol derivatives, characterized in that an aldehyde of the following formula (2-1)

(Formula 2-1)



in which R_5 and R_6 represent a hydrogen atom or a hydroxyl-protective group, respectively, and they are independent of each other or form a ring,


is reacted with a nitro alkane derivative of the following formula (3)




in which R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group, in the presence of a rare earth metal complex having an optically active ligand.

16. A process for stereoselectively producing optically active nitro alcohol derivatives, characterized in that an aldehyde of the following formula (2-2)

(Formula 2-2)




in which R_1 and R_2 represent a hydrogen atom or a hydroxyl-protective group, respectively, and they are independent of each other or form a ring, is reacted with a nitro alkane derivative of the following formula (3)



in which R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group, in the presence of a rare earth metal complex having an optically active ligand.

17. A process for stereoselectively producing optically active nitro alcohol derivatives, characterized in that an aldehyde of the following formula (2-3)

(Formula 2-3)



in which R_1 and R_2 represent a hydrogen atom or a hydroxyl-protective group, respectively, and they are independent of each other or form a ring, is reacted with a nitro alkane derivative of the following formula (3)




in which R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group,

in the presence of a rare earth metal complex having an optically active ligand.

18. A process for stereoselectively producing optically active nitro alcohol derivatives, characterized in that an aldehyde of the following formula (2-4)

(Formula 2-4)




in which R_1 represents a hydrogen atom or a hydroxyl-protective group,
is reacted with a nitro alkane derivative of the following formula (3)



in which R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group,
in the presence of a rare earth metal complex having an optically active ligand.

19. A process for stereoselectively producing optically active nitro alcohol derivatives, characterized in that, when producing the optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivative according to claim 6, an aldehyde of the following formula (4)


(Formula 4)



is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.

20. A process for stereoselectively producing optically active nitro alcohol derivatives, characterized in that, when producing the optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivative according to claim 7, an aldehyde of the following formula (5)


(Formula 5)



is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.

21. A process for stereoselectively producing optically active nitro alcohol derivatives, characterized in that, when producing the optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivative according to claim 8, an aldehyde of the following formula (6)


(Formula 6)



is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.

22. A process for stereoselectively producing optically active nitro alcohol derivatives, characterized in that, when producing the optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivative according to claim 9, an aldehyde of the following formula (7)


(Formula 7)



is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.

23. A process for stereoselectively producing optically active nitro alcohol derivatives, characterized in that, when producing the optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivative according to claim 10, an aldehyde of the following formula (8)


(Formula 8)



is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.

24. A process for stereoselectively producing optically active nitro alcohol derivatives, characterized in that, when producing the optically active 1-(3-hydroxymethyl-4-hydroxyphenyl)-2-nitro alcohol derivative according to claim 11, an aldehyde of the following formula (9)


(Formula 9)



is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.

25. A process for stereoselectively producing optically active nitro alcohol derivatives, characterized in that, when producing the optically active 1-(3,5-dihydroxyphenyl)-2-nitro alcohol derivative according to claim 12, an aldehyde of the following formula (10)


(Formula 10)



is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.

26. A process for stereoselectively producing optically active nitro alcohol derivatives, characterized in that, when producing the optically active 1-(4-hydroxyphenyl)-2-nitro alcohol derivative according to claim 13, an aldehyde of the following formula (11)


(Formula 11)



is reacted with nitromethane in the presence of a rare earth metal complex having an optically active ligand.


27. The process according to any one of claims 14 to 26, characterized in that said rare earth metal complex is a rare earth metal complex having an optically active ligand prepared from an alkoxide of Y, La, Nd, Sm, Eu, Gd, Tb, Dy, Pr or Yb or a trichloride of this rare earth metal, an optically active 1,1'-bi-2-naphthol derivative of the following formula (12)

(Formula 12)



or
the following formula (13)

(Formula 13)




in which R_7 and R_8 independently represent a hydrogen atom, an alkyl group of $C_1 - C_4$, an ethynyl group, a tri-alkylsilyl ethynyl group, or a phenyl group, and R_7 can be at any one of 4, 5, 6, and 7 positions and R_8 at any one of 4', 5', 6', and 7' positions, and an alkaline metal compound of lithium, sodium or potassium.

28. The process for stereoselectively producing optically active nitro alcohols according to any one of claims 14 to 26, characterized in that a rare earth metal complex is used which is prepared in such a way that the composition ratio of an alkoxide or a trichloride of the above rare earth metal: an optically active 1,1'-bi-2-naphthol compound: an alkaline metal is 1:1 - 3:0 - 10.

29. The optically active 1-substituted phenyl-2-amino alcohol derivatives characterized by the following formula (14)


(Formula 14)



in which n and m represent the positive integers satisfying $0 < n + m \leq 5$; R_1 and R_2 represent a hydrogen atom or a hydroxyl-protective group, respectively, and when $n + m$ is 2 or more, R_1 and R_2 are independent of each other or form a ring among R_1 s, among R_2 s, and among R_1 (s) and R_2 (s); R_3 represents $-(CH_2)_l-$ in which l is 0, 1, 2 or 3; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group.

30. The optically active 1-(3,4-dihydroxyphenyl)-2-amino alcohol derivatives characterized by the following formula (14-1)


(Formula 14-1)



in which R_5 and R_6 represent a hydrogen atom or a hydroxyl-protective group, respectively, and they are independent of each other or form a ring; R_4 represents a hydrogen atom, an alkyl group, or a hydroxymethyl group.


31. A process for producing optically active amino alcohols, characterized in that, when producing the optically active 1-substituted phenyl-2-amino alcohol derivative according to claim 29, the optically active 1-substituted phenyl-2-nitro alcohol derivative according to claim 1 is reduced stereoselectively.
32. A process for producing optically active amino alcohols, characterized in that, when producing the optically active 1-(3,4-dihydroxyphenyl)-2-amino alcohol derivative according to claim 30, the optically active 1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivative according to claim 2 is reduced stereoselectively.
33. A process for producing (R)-albutamin having the following formula (15),

(Formula 15)




characterized in that the (R)-1-(3,4-dihydroxyphenyl)-2-amino alcohol derivative of the following formula (14-2)

(Formula 14-2)




is used as a raw material which is obtained by reducing the (R)-1-(3,4-dihydroxyphenyl)-2-nitro alcohol derivative of the following formula (1-5).

(Formula 1-5)




34. A process for producing (R)-salmeterol having the following formula (16),

(Formula 16)




15 characterized in that the (R)-1-(3-hydroxymethyl-4-hydroxyphenyl)-2-amino alcohol derivative of the following formula (14-3)

(Formula 14-3)



30 is used as a raw material which is obtained by reducing the (R)-1-(3-hydroxymethyl-4-hydroxyphenyl)-2-nitro alcohol derivative of the following formula (1-6).

(Formula 1-6)



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP97/04240

A. CLASSIFICATION OF SUBJECT MATTER Int. Cl.⁶ C07C205/32, C07C205/40, C07C201/12, C07F7/18, C07D317/52, C07D319/08, C07C215/60, C07C217/10, C07C213/02, C07B61/00, B01J31/22
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) Int. Cl.⁶ C07C205/32, C07C205/40, C07C201/12, C07F7/18, C07D317/52, C07D319/08, C07C215/60, C07C217/10, C07C213/02, C07B61/00, B01J31/22

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CA (STN), REGISTRY (STN), WPI (DIALOG)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, 5514694, A (Georgia Tech Research Corp.), May 7, 1996 (07. 05. 96) (Family: none)	29 - 30
X	JP, 7-242543, A (Taiho Pharmaceutical Co., Ltd.), September 19, 1995 (19. 09. 95) (Family: none)	29 - 30
X	XUMIAO ZHAO et al., "A PRACTICAL SYNTHESIS OF 4-(3',4'-DIHYDROXYLPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE", Org. Prep. Proced. Int. (1995), Vol. 27, No. 4, pages 513 to 516	29 - 30
X	KJELL NAGREN et al., "Selective Synthesis of Racemic 1- ¹⁴ C-Labelled Norepinephrine, Octopamine, Norphenylephrine and Phenylethanolamine using (¹⁴ C)Nitromethane", Appl. Radiat. Isot. (1994), Vol. 45, No. 4, pages 515 to 521	1-2, 9-10, 14-15, 22-23, 29-32
Y		33 - 34

☒ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search.

February 12, 1998 (12. 02. 98)

Date of mailing of the international search report

February 24, 1998 (24. 02. 98)

Name and mailing address of the ISA/

Japanese Patent Office

Facsimile No.

Authorized officer

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP97/04240

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	S.V. KULIKOV et al., "SYNTHESIS OF 3-O-METHYLATED DERIVATIVES OF CATECHOLAMINES", Zh. Org. Khim. (1992), Vol. 28, No. 2, pages 348 to 358	1-2, 14-15
X	DOOSEOP KIM et al., "SYNTHESIS OF TUNICHROMES Mm-1 AND Mm-2, BLOOD PIGMENTS OF THE IRON-ASSIMILATING TUNICATE, MOLGULA MANHATTENSIS", Tetrahedron Lett. (1990), Vol. 31, No. 49, pages 7119 to 7122	29 - 30
X	CHEM. ABSTR., Vol. 105, No. 19, 10 November 1986 (Columbus, OH, USA), page 715, column 2, the abstract No. 172151c, YANG, P.W. et al. 'Improved synthesis of adrenaline', Hua Hsueh, 1985, 43(1), 19-29(Ch).	1-2, 9, 14-15, 22, 29-32
Y		33 - 34
X	MASAHIRO NAKAMURA et al., "Postharvest Berry Drop of Seedless Berries Produced by GA Treatment in Grape Cultivar 'Kyoho'", Tohoku J. Agric. Res. (1985), Vol. 35, Nos. 2 to 4, pages 81 to 89	1-2, 7, 14-15, 20
X	JP, 58-203950, A (Ohta Pharmaceutical Co., Ltd.), November 28, 1983 (28. 11. 83) (Family: none)	1-2, 14-15, 29-32
Y		33 - 34
X	JP, 57-16864, A (SmithKline Corp.), January 28, 1982 (28. 01. 82) & US, 4340600, A	29 - 30
X	GERARD LECLERC et al., "Synthesis and Structure-Activity Relationships among α -Adrenergic Receptor Agonists of the Phenylethanolamine Type", J. Med. Chem. (1980), Vol. 23, No. 7, pages 738 to 744	1-2, 14-15, 29-32
Y		33 - 34
X	CHEM. ABSTR., Vol. 88, No. 3, 16 January 1978 (Columbus, OH, USA), page 583, column 2, the abstract No. 22320y, SIATRA T et al., 'Derivatives of 1-(3',4'-dimethoxyphenyl)-2-aminoacetylaminioethanol', Chem. Chron. 1977, 6(3), 471-477 (Eng).	1-2, 7, 14-15, 20, 29-32
Y		33 - 34
X	WO, 96/35685, A1 (Nisshin Flour Milling Co., Ltd.), November 14, 1996 (14. 11. 96) (Family: none)	29 - 30

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP97/04240

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	THOMAS I. CROWELL et al., "A Kinetic Analysis of Nitrostyrene Hydrolysis and the Knoevenagel Condensation", J. Amer. Chem. Soc. (1973), Vol. 95, no. 20, pages 6781 to 6786	1, 10, 14, 23
X	DE, 2229894, A1 (Kyowa Hakko Kogyo Co., Ltd., Tokyo), June 19, 1972 (19. 06. 72) & US, 4147799, A & JP, 41-47799, A & JP, 48-010071, A & JP, 48-010072, A	1, 10, 14, 23, 29, 31
X	CHEM. ABSTR., Vol. 67, No. 7, 14 August 1967 (Columbus, OH, USA), page 3058, column 1-2, the abstract number No. 32454a, KARL WISMAYR et al., 'Phenylnitroethanols', Ger.1233410 (Cl.C07C), Feb. 2, 1967, Appl. June 15, 1961	1, 4, 12, 14, 17, 25
Y	JP, 2-17048, A (Gensia Pharmaceuticals, Inc.), January 22, 1990 (22. 01. 90) & US, 5108363, A	33
Y	JP, 6-87800, A (Glaxo Group Ltd.), March 29, 1994 (29. 03. 94) & US, 4992474, A	34